Waters Posts 7 Percent Rise in Q2 Revenues, Announces Acquisition of REIMS Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the second quarter were up 7 percent, driven by broad-based pharmaceutical demand and strong US sales.

The company posted Q2 revenues of $481.8 million, up from $451.1 million in Q2 2013 and beating the average Wall Street estimate of $476.1 million.

It reported a profit of $96.5 million, or $1.13 per share, during the quarter, compared to a profit of $89.3 million, or $1.03 per share, a year ago. On a non-GAAP basis, Waters had EPS of $1.22, beating the average analyst estimate of $1.21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.